Ertumaxomab

Ertumaxomab
Monoclonal antibody
Type	Trifunctional antibody
Source	Rat/mouse hybrid
Target	HER2/neu, CD3
Clinical data
Trade names	Rexomun
ATC code	none;
Identifiers
CAS Number	509077-99-0 ;
ChemSpider	none;
UNII	L5L45YGP1O;
	(what is this?) (verify)

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]^: 35)

References

Fresenius
ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
"2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Fresenius

[2] ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

[3] "2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.